SEARCH:   Advanced

Blood, 1 July 2004, Vol. 104, No. 1, pp. 243-249. Prepublished online as a Blood First Edition Paper on March 18, 2004; DOI 10.1182/blood-2003-12-4197. This Article Full Text (PDF) All Versions of this Article: 2003-12-4197v1 104/1/243    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Au, W.-Y. Articles by Kwong, Y.-L. Search for Related Content PubMed PubMed Citation Articles by Au, W.-Y. Articles by Kwong, Y.-L. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 8, 2003 Accepted February 17, 2004 Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients Wing-Yan Au, Annie Pang, Carolyn Choy, Chor-Sang Chim, and Yok-Lam Kwong* Department of Medicine, University of Hong Kong, Hong Kong, China Department of Pathology, University of Hong Kong, Hong Kong, China * Corresponding author; email: ylkwong{at}hkucc.hku.hk. In Epstein-Barr-virus (EBV)-positive lymphomas in immunocompetent patients, release of EBV DNA from tumor cells into the plasma might be useful for disease monitoring and prognostication. To test this hypothesis, we quantified serially plasma EBV DNA by quantitative-polymerase-chain-reaction in 39 cases of EBV-positive (natural-killer (NK) cell: n=23; T-cell: n=8; B-cell: n=4; Hodgkin: n=4) lymphomas. As control, EBV DNA was undetectable in 34 cases of EBV-negative lymphomas at diagnosis and during chemotherapy. In all cases of EBV-positive lymphomas, EBV DNA was detectable (105 to 1010 copies/ml) at diagnosis. It paralleled the clinical course, with EBV DNA becoming undetectable at remission, and remaining elevated in refractory disease. On multivariate analysis, high presentation EBV DNA (>7.3 x 107 copies/ml) was significantly associated with an inferior overall-survival (OS). Subgroup analysis of NK cell lymphomas, the largest cohort in this study, showed that presentation EBV DNA was correlated with disease stage and lactate dehydrogenase. On multivariate analysis, high presentation EBV DNA (>6.1 x 107 copies/ml) was significantly associated with an inferior disease-free-survival. During treatment, patients with EBV DNA that showed further increases or failed to become undetectable had significantly inferior OS. In EBV-positive lymphomas, plasma EBV DNA is valuable as a tumor biomarker and for prognostication. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Molecular monitoring of EBV-positive lymphoma Jan J. Cornelissen Blood 2004 104: 9. [Full Text] [PDF] This article has been cited by other articles: M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF] W.-y. Au, D. D. Weisenburger, T. Intragumtornchai, S. Nakamura, W.-S. Kim, I. Sng, J. Vose, J. O. Armitage, R. Liang, and for the International Peripheral T-Cell Lymphoma P Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project Blood, April 23, 2009; 113(17): 3931 - 3937. [Abstract] [Full Text] [PDF] L. Shen, W.-Y. Au, K.-Y. Wong, N. Shimizu, J. Tsuchiyama, Y.-L. Kwong, R. H. Liang, and G. Srivastava Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells Mol. Cancer Ther., December 1, 2008; 7(12): 3807 - 3815. [Abstract] [Full Text] [PDF] T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group Ann. Onc., August 1, 2008; 19(8): 1477 - 1484. [Abstract] [Full Text] [PDF] M. L. Gulley and W. Tang Laboratory Assays for Epstein-Barr Virus-Related Disease J. Mol. Diagn., July 1, 2008; 10(4): 279 - 292. [Abstract] [Full Text] [PDF] S. Park, J. Lee, Y. H. Ko, A. Han, H. J. Jun, S. C. Lee, I. G. Hwang, Y. H. Park, J. S. Ahn, C. W. Jung, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma Blood, August 1, 2007; 110(3): 972 - 978. [Abstract] [Full Text] [PDF] J. Lee, C. Suh, J. Huh, H. J. Jun, K. Kim, C. Jung, K. Park, Y. H. Park, Y. H. Ko, and W. S. Kim Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type Clin. Cancer Res., June 1, 2007; 13(11): 3250 - 3254. [Abstract] [Full Text] [PDF] J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF] M. L. Gulley, H. Fan, and S. H. Elmore Validation of Roche LightCycler Epstein-Barr Virus Quantification Reagents in a Clinical Laboratory Setting J. Mol. Diagn., November 1, 2006; 8(5): 589 - 597. [Abstract] [Full Text] [PDF] J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF] M. K. Gandhi, E. Lambley, J. Burrows, U. Dua, S. Elliott, P. J. Shaw, H. M. Prince, M. Wolf, K. Clarke, C. Underhill, et al. Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma Clin. Cancer Res., January 15, 2006; 12(2): 460 - 464. [Abstract] [Full Text] [PDF] T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type Blood, December 1, 2005; 106(12): 3785 - 3790. [Abstract] [Full Text] [PDF] C-S Chim, E S K Ma, F Loong, and Y-L Kwong Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement J. Clin. Pathol., April 1, 2005; 58(4): 443 - 445. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020